NANJING, China, June 1, 2023 /PRNewswire/ — Vazyme (688105.SH), China’s leading biotech company, has officially signed a global strategic cooperation agreement with Azenta Life Sciences (“Azenta”, Nasdaq: AZTA ), which will promote the establishment of a “one-stop” service process for both companies in the fields of next-generation sequencing, automated library preparation, raw material supply, experimental consumables, sample storage, and more.
Dr. Nie Junwei, CEO of Life Sciences Division, Vazyme, and George Ge, CEO of Azenta China, witnessed by Dr. Cao Lin, Chairman and Founder of Vazyme, and Stephen S. Schwartz, Global Chairman and CEO of Azenta, signed the agreement on behalf of both parties.
Vazyme, a global supplier specializing in the design, manufacture and application of bioactive compounds, is committed to expanding the application fields of leading technologies in life sciences, in vitro diagnostics, biomedicine and others. Leveraging its expertise in bioactive compounds, Vazyme is developing innovative biosolutions to drive research and development in the life sciences.
US-based Azenta is a global leader in life science solutions, providing innovative and reliable solutions for research and sample handling. Azenta’s sample screening and management solutions will accelerate breakthrough breakthroughs and therapies to market with greater speed and accuracy, and the company has established long-term partnerships with many multinational corporations and higher education institutions.
“We are very pleased to achieve this global strategic cooperation, as partners with a strong foundation for cooperation: Vazyme had established a deep collaboration with GENEWIZ (Azenta’s genomics service) in 2016, we believe that the new cooperation initiative will broaden and deepen further the cooperation between Vazyme and Azenta,” said Dr. Nie, CEO of the Life Sciences Division, Vazyme.
Vazyme: Global Roadmap Acceleration with Controllable Upstream Technology Development and End Product Manufacturing Capabilities
Vazyme posted strong financial performance in 2022. The company’s operating income reached US$517.25 million, up 90.99% year-on-year, and its regular business income of US$146.96 million increased 41 .03% YoY. Life sciences, in vitro diagnostics and biomedicine were the business sectors with the top three growth and performance.
Vazyme’s strong financial performance in 2022 can be attributed to its focus on innovation and investment in cutting-edge technologies. To meet the diverse needs of customers and partners, Vazyme invested a total of US$57.39 million in R&D in 2022, up 71.98% year-on-year, and its R&D team now has 1,196 researchers. By the end of 2022, Vazyme has obtained 109 patents, including 53 invention patents, and built state-of-the-art R&D and production facilities that will meet various product needs.
Vazyme strives to offer comprehensive solutions tailored to the diverse needs of customers by leveraging its core technologies and aims to strongly improve public health together with its partners towards a healthier, safer and greener future.
Looking to the future, Vazyme and Azenta will carry out global cooperation in the fields of automated sample solutions, oligo synthesis, molecular biology services and GLP standard specification services, fully integrating the resources and advantages of both companies to lead innovative advances, jointly developing international markets, and contributing to the life and health of all people.
About Vazyme
Established in 2012, Vazyme (688105.SH) is a global provider of enzyme-based biosolutions with more than 200 types of recombinant genetically modified enzymes, more than 1,000 types of high-performance materials, and more than 1,000 end products. It was listed on the Shanghai Stock Exchange in 2021.
With a mission to create value for customers by pursuing the highest standards in product and service quality, the company now serves customers in more than 60 countries and regions around the world.
Photo – https://mma.prnewswire.com/media/2089375…
View original content: https://www.prnewswire.com/news-releases/vazyme-firma-un-acuerdo-de-cooperacion-estrategica-global-con-azenta-301839562.html
